Tatva Chintan Pharma Chem Limited Total Liabilities
Tatva Chintan Pharma Chem Limited total liabilities. Based on the latest financial reports, Tatva Chintan Pharma Chem Limited (TATVA) has total liabilities worth Rs1.53 Billion INR (≈ $16.58 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tatva Chintan Pharma Chem Limited (TATVA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tatva Chintan Pharma Chem Limited (2018–2025)
Total liabilities of Tatva Chintan Pharma Chem Limited from 2018 to 2025. This chart illustrates how Tatva Chintan Pharma Chem Limited's total liabilities have evolved over time, based on quarterly financial data.
Tatva Chintan Pharma Chem Limited Competitors by Total Liabilities
The table below lists competitors of Tatva Chintan Pharma Chem Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hansa Biopharma AB
ST:HNSA
|
Sweden | Skr1.28 Billion |
|
PCL Technologies Inc
TW:4977
|
Taiwan | NT$1.25 Billion |
|
Shanghai Rongtai Health Tech
SHG:603579
|
China | CN¥1.12 Billion |
|
Precious Shipping Public Company Limited
BK:PSL
|
Thailand | ฿9.21 Billion |
|
Malteries Franco-Belges Société Anonyme
PA:MALT
|
France | €30.52 Million |
|
Hoang Huy Investment Financial
VN:TCH
|
Vietnam | ₫6.85 Trillion |
|
Bandwidth Inc
NASDAQ:BAND
|
USA | $640.59 Million |
|
RADIANCE HLDGS GRP.HD-01
F:RDH
|
Germany | €62.18 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Tatva Chintan Pharma Chem Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Tatva Chintan Pharma Chem Limited asset portfolio.
Liquidity & Leverage Metrics
Tatva Chintan Pharma Chem Limited Total Liabilities Ratios Explained
Tatva Chintan Pharma Chem Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tatva Chintan Pharma Chem Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tatva Chintan Pharma Chem Limited (2018–2025)
The table below shows the annual total liabilities of Tatva Chintan Pharma Chem Limited from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs974.25 Million ≈ $10.54 Million |
+19.34% |
| 2024-03-31 | Rs816.36 Million ≈ $8.83 Million |
-66.20% |
| 2023-03-31 | Rs2.42 Billion ≈ $26.12 Million |
+30.40% |
| 2022-03-31 | Rs1.85 Billion ≈ $20.03 Million |
+24.44% |
| 2021-03-31 | Rs1.49 Billion ≈ $16.10 Million |
+13.41% |
| 2020-03-31 | Rs1.31 Billion ≈ $14.19 Million |
+21.74% |
| 2019-03-31 | Rs1.08 Billion ≈ $11.66 Million |
+26.46% |
| 2018-03-31 | Rs852.48 Million ≈ $9.22 Million |
-- |
About Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and br… Read more